BioMarin Pharmaceutical Inc. (BMRN)
BMV
Closed
Aug 21, 2026
Day's Range
1,126.1552 wk Range
959.00Overview - BMRN - BioMarin Pharmaceutical Inc.
Key Statistics
Valuation
Enterprise Value
3.74T
P/E (Trailing)
‪178.64‬
PEG Ratio
‪-2.18‬
Price / Sales (TTM)
‪64.05‬
Price / Book
‪2.04‬
EV / EBITDA
‪343.28‬
Profitability
Gross Margin
‪79.50%‬
Profit Margin
‪2.14%‬
Operating Margin
‪21.16%‬
Return on Assets
‪3.25%‬
Return on Equity
‪1.18%‬
Ownership
Shares Outstanding
193.28M
Float
192.39M
Held by Insiders
‪0.34%‬
Held by Institutions
‪103.75%‬
Price stats
Beta
‪0.22‬
50-Day Avg
‪998.90‬
200-Day Avg
‪991.92‬
Dividends
Payout Ratio
‪0.00%‬
Shariah Compliance
Report Date: Feb 17, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - BMRN - BioMarin Pharmaceutical Inc.
Peers - BMRN - BioMarin Pharmaceutical Inc.
Peer Comparison
Compared with companies in Biotechnology listed on BMV.
- BMRNBMVBioMarin Pharmaceutical Inc.218.20BMarket Cap+4.43%52-week change178.64P/E (Trailing)‪2.14%‬Profit Margin
- ARGXNBMVargenx SE American Depositary Receipt931.67BMarket Cap+4.58%52-week change33.44P/E (Trailing)‪32.26%‬Profit Margin
- ALNYBMVAlnylam Pharmaceuticals Inc742.50BMarket Cap-54.26%52-week change57.14P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNBMVBioNTech SE492.36BMarket Cap+4.53%52-week change1.65P/E (Trailing)‪-63.63%‬Profit Margin
- ACADBMVAcadia Pharmaceuticals Inc.77.69BMarket Cap-12.18%52-week change13.49P/E (Trailing)‪33.41%‬Profit Margin
- AGIOBMVAgios Pharmaceuticals Inc.72.95BMarket Cap+0.00%52-week change5.17P/E (Trailing)‪88.25%‬Profit Margin
- ARWRBMVArrowhead Pharmaceuticals Inc.64.20BMarket Cap+0.00%52-week change-45455.00P/E (Trailing)‪-47.79%‬Profit Margin
Profile Summary - BMRN - BioMarin Pharmaceutical Inc.
About
BioMarin Pharmaceutical Inc. is a leading global biotechnology company specializing in the development and commercialization of therapies for people with serious and life-threatening rare genetic diseases. Its portfolio includes eight approved treatments targeting conditions such as mucopolysaccharidosis types I, IVA,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
